Saudi Arabian company Lifera is partnering with Sanofi and Arabio to strengthen local manufacturing of vaccines in Saudi Arabia.
Under the terms of the Memorandum of Understanding (MOU), Lifera, Sanofi and Arabio will explore opportunities for collaboration to help advance Saudi Arabia’s vaccines localisation strategy through a range of proposed initiatives.
Dr Ibrahim Aljufalli, Chairman of the Lifera Board, said: “As a newly established biopharmaceutical company, we are committed to working with global and local partners to achieve our mission – and this MOU is a testament to that commitment. By collaborating with Sanofi, an innovative global healthcare leader, Lifera is facilitating the transfer of world-class technology and expertise to Saudi Arabia and most importantly, bringing the highest-quality vaccines to Saudi citizens, enhancing national resilience and self-sufficiency. Lifera is committed to building manufacturing capacity to cGMP standards with international partners, and at the right scale to serve Saudi and global markets.”
The MOU reflects Lifera’s strategic mission to increase national resilience and grow the biopharma sector by enabling technology transfer, the creation of a skilled biopharmaceutical workforce and advancing Saudi Arabia’s Vision 2030.
Fokion Sinis, Vaccines General Manager for Sanofi Greater Gulf, commented: “Sanofi is committed to increasing vaccine accessibility and supporting Saudi Arabia’s goal to reduce its reliance on pharmaceutical imports. This MOU further builds on this commitment, enabling us to share our global expertise and contribute to advancing the public health agenda and industrial sector development of the country, ultimately benefitting patients and communities in Saudi Arabia.”
